BR0107696A - Derivados de glicosaminoglicans parcialmente dessulfatados dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante - Google Patents

Derivados de glicosaminoglicans parcialmente dessulfatados dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante

Info

Publication number
BR0107696A
BR0107696A BR0107696-5A BR0107696A BR0107696A BR 0107696 A BR0107696 A BR 0107696A BR 0107696 A BR0107696 A BR 0107696A BR 0107696 A BR0107696 A BR 0107696A
Authority
BR
Brazil
Prior art keywords
derivatives
endowed
devoid
antiangiogenic activity
anticoagulant effect
Prior art date
Application number
BR0107696-5A
Other languages
English (en)
Inventor
Benito Casu
Giangiacomo Torri
Anna Maria Naggi
Giuseppe Giannini
Claudio Pisano
Sergio Penco
Original Assignee
Sigma Tau Ind Farmaceuthiche R
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuthiche R filed Critical Sigma Tau Ind Farmaceuthiche R
Publication of BR0107696A publication Critical patent/BR0107696A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Abstract

"DERIVADOS DE GLICOSAMINOGLICANS PARCIALMENTE DESSULFATADOS DOTADOS COM ATIVIDADE ANTIANGIOGêNICA E DESTITUìDOS DE EFEITO ANTICOAGULANTE". Derivados glicosaminoglican parcialmente dessulfatados são descritos, particularmente heparina, e mais particularmente compostos de fórmula (I), em que os grupos U, R e R~ 1~ têm os significados indicados na descrição. Os ditos derivados glicosaminoglican são dotados com atividade antiangiogênica e são destituídos de atividade anticoagulante.
BR0107696-5A 2000-01-25 2001-01-24 Derivados de glicosaminoglicans parcialmente dessulfatados dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante BR0107696A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2000RM000041A IT1316986B1 (it) 2000-01-25 2000-01-25 Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
PCT/IT2001/000034 WO2001055221A1 (en) 2000-01-25 2001-01-24 Derivatives of partially desulphated glycosaminoglycans endowed with antiangiogenic activity and devoid of anticoagulating effect

Publications (1)

Publication Number Publication Date
BR0107696A true BR0107696A (pt) 2002-10-15

Family

ID=11454382

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0107696-5A BR0107696A (pt) 2000-01-25 2001-01-24 Derivados de glicosaminoglicans parcialmente dessulfatados dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante

Country Status (22)

Country Link
US (4) US20030013682A1 (pt)
EP (1) EP1268558B1 (pt)
JP (1) JP5371167B2 (pt)
KR (1) KR100812406B1 (pt)
CN (1) CN100540570C (pt)
AT (1) ATE348115T1 (pt)
AU (1) AU782632B2 (pt)
BR (1) BR0107696A (pt)
CA (1) CA2397964C (pt)
CY (1) CY1108001T1 (pt)
CZ (1) CZ303030B6 (pt)
DE (1) DE60125154T2 (pt)
DK (1) DK1268558T3 (pt)
ES (1) ES2277911T3 (pt)
HK (1) HK1051867A1 (pt)
HU (1) HU229509B1 (pt)
IT (1) IT1316986B1 (pt)
MX (1) MXPA02007195A (pt)
PL (1) PL209479B1 (pt)
PT (1) PT1268558E (pt)
SK (1) SK287566B6 (pt)
WO (1) WO2001055221A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
ES2431362T3 (es) * 2001-09-12 2013-11-26 Sigma-Tau Research Switzerland S.A. Derivados de glicosaminoglicanos totalmente N-desulfatados como agentes inhibidores de la heparanasa, dotados con actividad antiangiogénica y desprovistos de efecto anticoagulante
AU2008202261B2 (en) * 2001-09-12 2011-07-28 Leadiant Biosciences S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
EP1765874A1 (en) 2004-03-26 2007-03-28 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
AU2008318343B2 (en) * 2007-11-02 2013-07-18 Dilafor Ab Non-anticoagulant polysaccharide compositions
US8569262B2 (en) * 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
ES2567079T3 (es) * 2007-11-02 2016-04-19 Momenta Pharmaceuticals, Inc. Composiciones de polisacáridos que no son anticoagulantes
US8592393B2 (en) * 2007-11-02 2013-11-26 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
CN102985443B (zh) 2010-04-16 2017-05-10 动量制药公司 组织靶向
US8431826B2 (en) 2010-05-14 2013-04-30 James Robert Howard Capacitive power and ground plane structure utilizing fractal elements for the reduction of radiated emissions
CA2795868A1 (en) 2010-06-17 2011-12-22 Momenta Pharmaceuticals, Inc. Methods and compositions for modulating hair growth
WO2013095215A1 (en) 2011-12-19 2013-06-27 Dilaforette Ab Low anticoagulant heparins
DK2794665T3 (da) 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
EP2797942B1 (en) 2011-12-28 2018-10-31 Galectin Therapeutics Inc. Composition of novel carbohydrate drug for treatment of human diseases
ES2848538T3 (es) 2012-06-06 2021-08-10 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de enfermedades asociadas con elevada óxido nítrico sintasa inducible
US9507912B2 (en) 2012-08-31 2016-11-29 Nuvectra Corporation Method and system of simulating a pulse generator on a clinician programmer
DK2900061T3 (da) 2012-09-17 2020-03-02 Galectin Therapeutics Inc Fremgangsmåde til forstærkning af specifikke immunterapier ved cancerbehandling
JP6055928B2 (ja) 2012-10-10 2016-12-27 ガレクティン・セラピューティクス・インコーポレイテッドＧａｌｅｃｔｉｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 糖尿病性腎症および関連障害の処置のためのガラクトース分枝炭水化物化合物
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
AU2014274377A1 (en) 2013-05-28 2015-11-12 Momenta Pharmaceuticals, Inc. Pharmaceutical compositions
JP6132302B2 (ja) * 2013-05-28 2017-05-24 リーディアント・バイオサイエンシーズ・ソシエタ・アノニマＬｅａｄｉａｎｔ Ｂｉｏｓｃｉｅｎｃｅｓ Ｓ．Ａ． 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
ITLO20130005A1 (it) 2013-10-31 2015-05-01 He E Biochimiche G Ronzonr S R Derivati di glucosamminoglicani n-desolfatati e loro uso come farmaci
ITLO20130006A1 (it) * 2013-11-06 2015-05-07 He E Biochimiche G Ronzoni S R Derivati carbossilati di glucosamminoglicani e loro uso come farmaci
CN103724458B (zh) * 2014-01-17 2016-03-30 福州大学 含n-非取代葡萄糖胺肝素六糖的制备及其纯化
HUE042681T2 (hu) 2015-03-06 2019-07-29 Leadiant Biosciences Sa In Liquidazione Myeloma multiplex roneparstat kombinációs terápiája
JP2016014148A (ja) * 2015-09-10 2016-01-28 シグマ−タウ・リサーチ・スウィッツァーランド・ソシエテ・アノニム 抗血管新生活性を有し、抗凝血効果を有さない、ヘパラナーゼ阻害剤としての部分的に脱硫酸化されたグリコサミノグリカンの誘導体
CN107177015A (zh) * 2016-03-11 2017-09-19 梁颖 一种重乙酰化肝素修饰物及其制备方法和应用
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
JP2020503377A (ja) 2016-12-13 2020-01-30 ベータ セラピューティクス プロプライアタリー リミティド ヘパラナーゼ阻害剤及びそれの使用
CN108424474B (zh) * 2017-02-15 2023-07-25 清华大学 去抗凝肝素衍生物及其用于炎症性肠病的治疗
CN111670038B (zh) * 2018-02-02 2024-01-26 深圳市海普瑞药业集团股份有限公司 糖胺聚糖衍生物及其制备方法和用途
EP3705126A1 (en) 2019-03-05 2020-09-09 Leadiant Biosciences S.p.A. Roneparstat for the treatment of amyloidosis
WO2021128253A1 (zh) * 2019-12-27 2021-07-01 深圳市海普瑞药业集团股份有限公司 一种糖胺聚糖衍生物及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4500519A (en) * 1978-11-06 1985-02-19 Choay S.A. Mucopolysaccharides having biological properties, preparation and method of use
US5262403A (en) 1986-03-10 1993-11-16 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II
IL79255A0 (en) 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
WO1988001280A1 (en) * 1986-08-21 1988-02-25 Board Of Regents, The University Of Texas System Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion
FR2614026B1 (fr) * 1987-04-16 1992-04-17 Sanofi Sa Heparines de bas poids moleculaire, a structure reguliere, leur preparation et leurs applications biologiques
US5280016A (en) * 1991-03-29 1994-01-18 Glycomed Incorporated Non-anticoagulant heparin derivatives
JPH05157344A (ja) * 1991-12-09 1993-06-22 Mitsubishi Heavy Ind Ltd 空気調和機の吹出口
JPH0512822A (ja) 1991-12-16 1993-01-22 Seiko Epson Corp カートリツジ
JPH06157344A (ja) * 1992-02-07 1994-06-03 Childrens Medical Center Corp:The 血管新生阻害のための医薬製剤及び血管新生阻害方法
US5668118A (en) * 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5296471A (en) 1992-12-22 1994-03-22 Glycomed Incorporated Method for controlling o-desulfation of heparin and compositions produced thereby
US5696100A (en) * 1992-12-22 1997-12-09 Glycomed Incorporated Method for controlling O-desulfation of heparin and compositions produced thereby
IT1264709B1 (it) 1993-07-12 1996-10-04 Italfarmaco Spa Derivati eparinici ad attivita' antimetastatica
US5583121A (en) * 1994-01-12 1996-12-10 Michigan State University Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
CA2189038A1 (en) * 1994-05-06 1995-11-09 Kevin R. Holme O-desulfated heparin derivatives, methods of making and uses thereof
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US5854221A (en) * 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
DE69705819T2 (de) * 1996-01-15 2002-04-11 Janssen Pharmaceutica N.V., Beerse Angiogenesis hemmende pyridazinamine
JP4051099B2 (ja) * 1997-01-31 2008-02-20 生化学工業株式会社 低分子化ヘパリン、その製造法及び医薬組成物
IT1296581B1 (it) 1997-11-28 1999-07-14 Istituto Scient Di Chimica E B Materiali polimerici non trombogenici e ad esaltata compatibilita' con fluidi e tessuti organici
IT1296998B1 (it) * 1997-12-19 1999-08-03 Derivati Organici Lab Composizione costituita da frazioni di eparina avente caratteristiche riproducibili con peso molecolare medio di 5200 d
IT1316986B1 (it) 2000-01-25 2003-05-26 Sigma Tau Ind Farmaceuti Derivati glicosamminoglicani parzialmente desolfatati nonanticoagulanti ad attivita' antiangiogenica.
US7781416B2 (en) * 2000-01-25 2010-08-24 Sigma-Tau Research Switzerland S.A. Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect

Also Published As

Publication number Publication date
CA2397964A1 (en) 2001-08-02
CN100540570C (zh) 2009-09-16
HUP0204196A2 (hu) 2003-03-28
US20050222084A1 (en) 2005-10-06
EP1268558A1 (en) 2003-01-02
JP2003523460A (ja) 2003-08-05
CA2397964C (en) 2010-10-12
PL357209A1 (en) 2004-07-26
JP5371167B2 (ja) 2013-12-18
SK287566B6 (sk) 2011-02-04
HK1051867A1 (en) 2003-08-22
DK1268558T3 (da) 2007-04-10
PL209479B1 (pl) 2011-09-30
US8222231B2 (en) 2012-07-17
MXPA02007195A (es) 2003-01-28
ITRM20000041A0 (it) 2000-01-25
ITRM20000041A1 (it) 2001-07-25
CZ303030B6 (cs) 2012-03-07
KR100812406B1 (ko) 2008-03-11
HUP0204196A3 (en) 2003-05-28
CY1108001T1 (el) 2013-09-04
IT1316986B1 (it) 2003-05-26
PT1268558E (pt) 2007-02-28
US7790700B2 (en) 2010-09-07
CZ20022308A3 (cs) 2003-01-15
HU229509B1 (en) 2014-01-28
DE60125154D1 (de) 2007-01-25
DE60125154T2 (de) 2007-10-25
SK10672002A3 (sk) 2002-12-03
US20050107331A1 (en) 2005-05-19
EP1268558B1 (en) 2006-12-13
US20100298263A1 (en) 2010-11-25
KR20020080381A (ko) 2002-10-23
ES2277911T3 (es) 2007-08-01
ATE348115T1 (de) 2007-01-15
US20030013682A1 (en) 2003-01-16
AU3406401A (en) 2001-08-07
AU782632B2 (en) 2005-08-18
WO2001055221A1 (en) 2001-08-02
CN1396930A (zh) 2003-02-12

Similar Documents

Publication Publication Date Title
BR0107696A (pt) Derivados de glicosaminoglicans parcialmente dessulfatados dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante
BR0117124A (pt) Derivados de glicosaminoglicanos parcialmente dessulfatados como inibidores da heparanase, dotados com atividade antiangiogênica e destituìdos de efeito anticoagulante
BR0111981A (pt) herbicidas de piridina substituìda
AU2002239841A1 (en) Proteoglycan compositions for treatment of inflammatory conditions
BR9912606A (pt) Parede divisória móvel
NO20006323L (no) Glykopeptid-derivater og farmasöytiske sammensetninger som inneholder disse
BR0116402A (pt) Derivados de tetrahidropiridina, sua preparação e sua utilização como inibidores de proliferação celular
BR0007527A (pt) Fenilfenantridinas com atividade inibitória depde-iv
BR9810450A (pt) Derivados de ácido barbitúrico com atividade antimetastática e antitumor
BR9913225A (pt) Novos agentes antibacterianos de isoxazolinona
BR9711117A (pt) Oligossacarídios modificados.
IT1290814B1 (it) Glicosaminoglicani aventi elevata attivita' antitrombotica
DE69708862D1 (de) Derivate von k5 polysaccharid mit hoher, blutgerinnungshemmender wirkung
BR0016553A (pt) 2-(1h-indol-3-il)-2-oxo-acetamidas com atividades antitumor
BRPI0415285A (pt) derivados de aminoalcanol
EA200000628A1 (ru) Ингибиторы металлопротеаз матрикса
ITMI20000665A0 (it) Glicosaminoglicani derivati dal polisaccaride k5 aventi elevata attivita' anticoagulante ed antitrombotica e processo per la loro preparazio
BRPI0415034A (pt) derivados de aminopiridina como inibidores de não-sintase induzìveis
BR9911769A (pt) Composições que contêm dextrina para prevenir as aderências cirúrgicas
EP1505079A3 (de) Heparin mit mittlerer Molmasse von 10 bis 11,5 kD
BR0013084A (pt) Heterociclil-2h-cromenos substituìdos
UY24915A1 (es) Derivados de benzoxazindiona, aplicación de los mismos y medicamentos que los contienen
PT1244614E (pt) Inibidores de triptase
BR9813897A (pt) Derivados de bifenila como farmacêuticos
FI19992274A (fi) Liitosyhde

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: E EM CONSONANCIA COM A RESOLUCAO NO 34 DO CGEN.

B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: REFERENTE A RPI 2107 DE 24/05/2011.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 16A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2394 DE 22-11-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.